Besides the motor and sensory dysfunctions, the progression of cognitive decline is a frequent manifestation of RRMS. Fatigue is another important symptom of MS, and can negatively affect subject's Quality of life (QoL) and socio-economic functioning, including the ability to work, independent of the direct effects of disability. This is a phase IV observational, non-interventional, prospective, multicentric study to evaluate cognition in RRMS subjects treated with Rebif and its relationship to the fatigue and neurological dysfunction status. The study plans to enroll 300 subjects, across 14 centres in Czech Republic, who will be prescribed with Rebif according to its summary of product characteristics (SmPC). Assessment of cognitive and fatigue status will be done at baseline and follow-up visits at Months 3, 6, 12, 24. Subjects will be selected using the convenience method following the non-probability sampling.
OBJECTIVES
Primary Objective:
* To assess changes of cognition \[measured by Paced Auditory Serial Addition Test (PASAT)\] in RRMS subjects treated with Rebif
Secondary Objectives:
* To assess changes of fatigue \[measured by Fatigue Descriptive Scale (FDS)\] in RRMS subjects treated with Rebif
* To assess a correlation between cognition, fatigue and neurological status in RRMS subjects treated with Rebif
* To assess a relationship between Rebif dosage \[22 mcg vs 44 mcg thrice a week (tiw)\] and cognition (PASAT)
* To assess a relationship between Rebif dosage (22 mcg vs 44 mcg tiw) and fatigue (FDS)
* To assess adherence to Rebif treatment
* To explore the use of antidepressive and antifatigue medicaments
